Breaking News Instant updates and real-time market news.

BMY

Bristol-Myers

$55.43

0.38 (0.69%)

14:29
10/09/16
10/09
14:29
10/09/16
14:29

Bristol-Myers reports Phase 3 data on Yervoy in melanoma, says boosts survival

Bristol-Myers Squibb announced "superior efficacy" with Yervoy 10 mg/kg versus placebo on all survival endpoints in the Phase 3 trial CA184-029 evaluating stage III melanoma patients who are at high risk of recurrence following complete surgical resection. In the study, Yervoy compared with placebo significantly improved overall survival, a secondary endpoint, with five-year OS rates at 65.4% in the Yervoy group and 54.4% in the placebo group. Distant metastasis-free survival, a secondary endpoint, was also significantly improved versus placebo and had five-year DMFS rates of 48.3% and 38.9% in the Yervoy and placebo groups, respectively. The median DMFS was 48.3 months with Yervoy versus 27.5 months with placebo. In this updated five-year analysis, the recurrence-free survival -- the primary endpoint -- benefit observed previously with Yervoy was maintained. Updated five-year results demonstrated RFS remained significantly longer for Yervoy versus placebo, with a median RFS of 27.6 months versus 17.1 months, respectively. The safety profile remained consistent with the initial analysis, with no new deaths or safety signals. These data were featured during the 2016 European Society for Medical Oncology Congress Press Program and simultaneously published in The New England Journal of Medicine.

  • 09

    Oct

  • 27

    Oct

  • 31

    Oct

  • 06

    Nov

BMY Bristol-Myers
$55.43

0.38 (0.69%)

09/12/16
JEFF
09/12/16
NO CHANGE
Target $57
JEFF
Hold
Jefferies cuts Bristol-Myers price target, upgrades AstraZeneca
Jefferies analyst Jeffrey Holford lowered his price target for Bristol-Myers Squibb (BMY) to $57 from $69 saying the stock is positioned for a "rough mid term ride." The analyst sees a "difficult catalyst" set for Bristol shares with "numerous" upcoming competitor read-outs in non-small cell lung cancer. The market could see worse than expected data from Bristol's CM-026 and CM-568 studies as well as better than expected data from AstraZeneca's (AZN) MYSTIC study and Roche's (RHHBY) Chemo-IO studies in the first half of 2017, Holford tells investors in a research note. He keeps a Hold rating on Bristol and upgraded this morning AstraZeneca to Buy from Hold. Holford prefers Astra for its immunology exposure.
09/20/16
SBSH
09/20/16
NO CHANGE
Target $70
SBSH
Buy
Bristol-Myers price target lowered to $70 from $75 at Citi
In a research note titled "Brace Yourself. Attractive Valuation but No Near-Term Respite.," Citi analyst Andrew Baum lowered his price target for shares of Bristol-Myers Squibb to $70 from $75. The analyst lowered his earnings forecasts by up to 8% to reflect the "limited supportive data" in the non-small cell lung cancer indication. Baum keeps a Buy rating on the shares as he views the valuation as attractive. He points out, however, the near-term news-flow is likely to be negative.
09/27/16
PIPR
09/27/16
NO CHANGE
Target $62
PIPR
Neutral
Bristol-Myers price target lowered to $62 from $65 at Piper Jaffray
Piper Jaffray analyst Richard Purkiss lowered his price target for Bristol-Myers Squibb (BMY) to $62 saying he sees the company ceding Opdivo's early-mover advantage in lung cancer to competitors. The analyst expects to see details from Roche's (RHHBY) positive OAK trial of Tecentriq vs. docetaxel in non-small cell lung cancer at the upcoming ESMO meeting. Purkiss also expects to see details from Merck's (MRK) positive KEYNOTE-024 trial of Keytruda. The analyst lowered his post-2016 Opdivo forecasts and reiterates a Neutral rating on Bristol shares.
09/28/16
ROTH
09/28/16
NO CHANGE
Target $23
ROTH
Buy
Nektar price target raised to $23 from $19 at Roth Capital
Roth Capital analyst Michael Higgins raised his price target for Nektar (NKTR) to $23 from $19 after the company and Bristol-Myers (BMY) announced a clinical collaboration to evaluate the combination of the latter's anti-PD-1 antibody, Opdivo, with NKTR-214. The analyst reiterates a Buy rating on Nektar's shares.

TODAY'S FREE FLY STORIES

UAA

Under Armour

$21.56

0.36 (1.70%)

, UA

Under Armour

$19.92

0.27 (1.37%)

06:27
06/27/17
06/27
06:27
06/27/17
06:27
Recommendations
Under Armour, Under Armour, Kohl's, Nike, adidas analyst commentary  »

Under Armour still…

UAA

Under Armour

$21.56

0.36 (1.70%)

UA

Under Armour

$19.92

0.27 (1.37%)

KSS

Kohl's

$37.52

0.49 (1.32%)

NKE

Nike

$53.28

0.43 (0.81%)

ADDYY

adidas

$94.38

-0.015 (-0.02%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Jun

LYV

Live Nation

$34.86

0.02 (0.06%)

06:20
06/27/17
06/27
06:20
06/27/17
06:20
Recommendations
Live Nation analyst commentary  »

Live Nation price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HLT

Hilton

$65.23

-0.17 (-0.26%)

, CHH

Choice Hotels

$66.25

-0.45 (-0.67%)

06:17
06/27/17
06/27
06:17
06/27/17
06:17
Recommendations
Hilton, Choice Hotels, Hyatt, Marriott analyst commentary  »

Deutsche…

HLT

Hilton

$65.23

-0.17 (-0.26%)

CHH

Choice Hotels

$66.25

-0.45 (-0.67%)

H

Hyatt

$58.09

0.39 (0.68%)

MAR

Marriott

$103.93

-0.13 (-0.12%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Jun

GOOGL

Alphabet Class A

$972.09

-14 (-1.42%)

06:14
06/27/17
06/27
06:14
06/27/17
06:14
Technical Analysis
Technical View: Alphabet Class A falls after EU fine, potential bearish pattern »

The shares were last down…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

OSUR

OraSure

$15.72

0.17 (1.09%)

06:10
06/27/17
06/27
06:10
06/27/17
06:10
Hot Stocks
OraSure's HIV self-test supported by Gates Foundation for accelerated adoption »

OraSure entered a new…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Jul

BABA

Alibaba

$142.73

-0.28 (-0.20%)

06:09
06/27/17
06/27
06:09
06/27/17
06:09
Initiation
Alibaba initiated  »

Alibaba resumed with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jun

RDWR

Radware

$17.94

-0.04 (-0.22%)

06:06
06/27/17
06/27
06:06
06/27/17
06:06
Hot Stocks
Radware granted ISO27017 and ISO27018 cloud services certifications »

Radware has achieved…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Jul

  • 13

    Jul

GRPN

Groupon

$3.45

-0.02 (-0.58%)

06:06
06/27/17
06/27
06:06
06/27/17
06:06
Recommendations
Groupon analyst commentary  »

Groupon trading well…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GDS

GDS Holdings

$8.83

-0.22 (-2.43%)

, BABA

Alibaba

$142.73

-0.28 (-0.20%)

06:05
06/27/17
06/27
06:05
06/27/17
06:05
Hot Stocks
GDS Holdings announces new order from Alibaba for Beijing 3 data center »

GDS Holdings (GDS)…

GDS

GDS Holdings

$8.83

-0.22 (-2.43%)

BABA

Alibaba

$142.73

-0.28 (-0.20%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jun

MCK

McKesson

$167.61

0.65 (0.39%)

06:04
06/27/17
06/27
06:04
06/27/17
06:04
Conference/Events
McKesson to host investor day »

Investor Day to be held…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jun

  • 26

    Jul

  • 30

    Jul

INFO

IHS Markit

$46.40

-0.15 (-0.32%)

06:04
06/27/17
06/27
06:04
06/27/17
06:04
Earnings
IHS Markit sees FY17 adjusted EPS $2.02-$2.08, consensus $2.06 »

Sees FY17 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Jun

UCBI

United Community Banks

$26.70

0.22 (0.83%)

, FOFN

Four Oaks Fincorp

$15.18

0.4 (2.71%)

06:03
06/27/17
06/27
06:03
06/27/17
06:03
Hot Stocks
United Community, Banks Four Oaks Fincorp announce merger agreement »

Community Banks (UCBI)…

UCBI

United Community Banks

$26.70

0.22 (0.83%)

FOFN

Four Oaks Fincorp

$15.18

0.4 (2.71%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

S

Sprint

$8.01

-0.04 (-0.50%)

, CMCSA

Comcast

$39.59

0.09 (0.23%)

06:03
06/27/17
06/27
06:03
06/27/17
06:03
Periodicals
Sprint enters wireless deal talks with Comcast, Charter, WSJ says »

Sprint (S) is negotiating…

S

Sprint

$8.01

-0.04 (-0.50%)

CMCSA

Comcast

$39.59

0.09 (0.23%)

CHTR

Charter

$332.65

1.85 (0.56%)

TMUS

T-Mobile

$63.15

-0.25 (-0.39%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Jul

  • 03

    Aug

INFO

IHS Markit

$46.40

-0.15 (-0.32%)

06:02
06/27/17
06/27
06:02
06/27/17
06:02
Earnings
IHS Markit reports Q2 adjusted EPS 52c, consensus 52c »

Reports Q2 revenue $906M,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Jun

UCBI

United Community Banks

$26.70

0.22 (0.83%)

06:00
06/27/17
06/27
06:00
06/27/17
06:00
Hot Stocks
Breaking Hot Stocks news story on United Community Banks »

United Community Banks,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SPX

S&P 500

06:00
06/27/17
06/27
06:00
06/27/17
06:00
Technical Analysis
S&P 500: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CTAS

Cintas

$129.50

0.09 (0.07%)

05:58
06/27/17
06/27
05:58
06/27/17
05:58
Downgrade
Cintas rating change  »

Cintas downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

STOR

Store Capital

$23.11

2.34 (11.27%)

05:54
06/27/17
06/27
05:54
06/27/17
05:54
Downgrade
Store Capital rating change  »

Store Capital downgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GOOG

Alphabet

$952.27

-13.32 (-1.38%)

, GOOGL

Alphabet Class A

$972.09

-14 (-1.42%)

05:53
06/27/17
06/27
05:53
06/27/17
05:53
Hot Stocks
Europe fines Google EUR 2.42B for breaching antitrust rules »

The European Commission…

GOOG

Alphabet

$952.27

-13.32 (-1.38%)

GOOGL

Alphabet Class A

$972.09

-14 (-1.42%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jun

  • 28

    Jun

  • 19

    Jul

GDX

Market Vector Gold Miners

$22.56

-0.18 (-0.79%)

05:52
06/27/17
06/27
05:52
06/27/17
05:52
Technical Analysis
Market Vector Gold Miners: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HCC

Warrior Met Coal

$16.19

-0.07 (-0.43%)

05:52
06/27/17
06/27
05:52
06/27/17
05:52
Downgrade
Warrior Met Coal rating change  »

Warrior Met Coal…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GLD

SPDR Gold Trust

$118.36

-1.07 (-0.90%)

05:52
06/27/17
06/27
05:52
06/27/17
05:52
Technical Analysis
SPDR Gold Trust: Pivot points, pivot high broken »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NUGT

Direxion Gold Miners Bull

$32.73

-0.87 (-2.59%)

05:51
06/27/17
06/27
05:51
06/27/17
05:51
Technical Analysis
Direxion Gold Miners Bull: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

JNUG

Direxion Daily Jr Gld Mnrs Bull 3X Shrs

$19.35

-0.65 (-3.25%)

05:50
06/27/17
06/27
05:50
06/27/17
05:50
Technical Analysis
Direxion Daily Jr Gld Mnrs Bull 3X Shrs: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DUST

Direxion Daily Gold Miners Bear 3X ETF

$29.23

0.76 (2.67%)

05:50
06/27/17
06/27
05:50
06/27/17
05:50
Technical Analysis
Direxion Daily Gold Miners Bear 3X ETF: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.